Neurological complications are reported in approximately 4% of people with severe COVID-19. New data reveal that treatment with dexamethasone or remdesivir during acute COVID-19 is associated with a reduced frequency of neurological complications, including stroke, seizures and meningitis. Importantly, the drugs showed a synergistic effect when used together. Moreover, dexamethasone treatment was associated with a decreased risk of neurological complications in individuals with non-hypoxic COVID-19.